Proactive Investors - Run By Investors For Investors

Over 75% of patients now enrolled into ANGLE’s Parsortix clinical study

Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019
blood cells
ANGLE’s technology allows scientists to harvest tumour cells in the bloodstream and analyse them

ANGLE PLC (LON:AGL) continues to make “good progress” with the enrolment for the clinical study of its Parsortix cancer detection technology.

So far, over 75% of the required 400 patients – 200 with cancer and 200 healthy – have been enrolled in the study.

READ: Scientists make major breakthrough with Parsortix

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019.

Away from the trial, ANGLE has been carrying out more work of its own on Parsortix, which has yielded “new insights” into the system.

Multi-billion-dollar market

“Our significant and sustained efforts to complete the clinical and analytical studies needed to support our FDA submission are progressing well,” said chief executive Andrew Newland.

“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.”

He added: “This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”

Shares fell 4.4% to 41.1p.

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

bacteria
December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use